In the world of biologics, MedImmune has established itself as a true visionary, with one of the most robust pipelines in the biopharmaceutical industry. From groundbreaking research and development, to state-of-the-art manufacturing, to product commercialization, every day MedImmune is touching lives. MedImmune is proudly united by the spirit of innovation, the heart of inspiration, and the strength of integration, as it advances science for better health.
Funded for three years by Biotechnology alumnus Dr Darrin M Disley, (CEO, Horizon Discovery Group Plc and MPhil Bioscience Enterprise Fellow), Christopher R. Lowe Carpe Diem Enterprise Program provides funding for bursaries, prizes and an annual innovation conference.
Darrin is a life scientist who has been involved in the start-up and growth of numerous business ventures. He has a track record of raising $200 million business financing from grant, angel, corporate, venture capital and public market sources as well as closing $350 million of product, service, and licensing deals. In 2012, he was named Business Leader of the Year at the European Life Science Awards and in 2014 was named Executive of the Year at the Scrip Awards a global award recognising leadership in biotechnology and pharmaceutical companies.